2. Academic Validation
  3. Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites

Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites

  • ACS Med Chem Lett. 2017 Feb 5;8(3):350-354. doi: 10.1021/acsmedchemlett.7b00011.
William Devine 1,  Sarah M Thomas 2,  Jessey Erath 3,  Kelly A Bachovchin 1,  Patricia J Lee 4,  Susan E Leed 4,  Ana Rodriguez 5,  Richard J Sciotti 4,  Kojo Mensa-Wilmot 2,  Michael P Pollastri 1
Affiliations

Affiliations

  • 1 Department of Chemistry & Chemical Biology, Northeastern University , 360 Huntington Avenue, Boston, Massachusetts 02115, United States.
  • 2 Department of Cellular Biology, University of Georgia , Athens, Georgia 30602, United States.
  • 3 Anti-Infectives Screening Core, New York University School of Medicine , New York, New York 10010, United States.
  • 4 Experimental Therapeutics, Walter Reed Army Institute for Research , 2460 Linden Lane, Silver Spring, Maryland 20910, United States.
  • 5 Department of Microbiology, Division of Parasitology, New York University School of Medicine, 341 East 25th Street New York, New York 10010, United States; Anti-Infectives Screening Core, New York University School of Medicine, New York, New York 10010, United States.
PMID: 28337329 DOI: 10.1021/acsmedchemlett.7b00011
Abstract

Human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis present a significant burden across the developing world. Existing therapeutics for these protozoal neglected tropical diseases suffer from severe side effects and toxicity. Previously, NEU-1045 (3) was identified as a promising lead with cross-pathogen activity, though it possessed poor physicochemical properties. We have designed a library of analogues with improved calculated physicochemical properties built on the quinoline scaffold of 3 incorporating small, polar aminoheterocycles in place of the 4-(3-fluorobenzyloxy)aniline substituent. We report the biological activity of these inhibitors against Trypanosoma brucei (HAT), T. cruzi (Chagas disease), and Leishmania major (cutaneous leishmaniasis) and describe the identification of N-(5-chloropyrimidin-2-yl)-6-(4-(morpholinosulfonyl)phenyl)quinolin-4-amine (13t) as a promising inhibitor of L. major proliferation and 6-(4-(morpholinosulfonyl)phenyl)-N-(pyrimidin-4-yl)quinolin-4-amine (13j), a potent inhibitor of T. brucei proliferation with improved drug-like properties.

Keywords

Antiparasitic agents; Chagas disease; Leishmania major; Plasmodium falciparum; Trypanosoma brucei; Trypanosoma cruzi; human African trypanosomiasis; leishmaniasis.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z